Qiagen announced today that the US Food and Drug Administration has approved the expanded use of the company’s Therascreen EGFR RGQ PCR Kit to allow its use as a companion diagnostic for Pfizer’s Vizimpro (dacomitinib) for first-line treatment of patients with non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutation.
{iframe}https://www.genomeweb.com/regulatory-news/fda-approves-expanded-use-qiagen-egfr-cdx-lung-cancer#.W7Ij0RNKhYg{/iframe}